Published in Cardiovascular Business Week, March 20th, 2007
"We are encouraged by these results, as BL-1040 is the first injectable liquid...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.